These neurotransmitter-cognition results are in line with previous reports e.g., dopamine and serotonin have previously been shown to be important for cognitive processes (e.g., [88–90]), VACHT dysfunction has been shown to be related to intellectual disabilities and Parkinson’s Disease, as well as to prefrontal cortex functioning [91, 92], acute CB1 disruption results in a decline in verbal learning and working memory performance [93], and NMDA has been selected as a promising target for cognitive enhancement e.g., in dementia [94, 95]. Here, SLC18A3 is linked to Parkinson disease.